Biotech Stock News (RVNC) (DNAI)

Revance Therapeutics (NASDAQ:RVNC) On Tuesday June 14, 2016 shares of Revance Therapeutics went down in after-hours trading by 24% after the company stated that it had failed to meet the primary endpoint of its phase 3 clinical trial. The phase 3 trial was testing patients with lateral catheral lines or Crows Feet. The trial used … Read more